Compare Sanofi SA (SNY) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.73. The key difference: Sanofi SA pays a 5.61% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals.
| SNY | VTIP | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | — |
52-Week High | $52.34 | $50.75 |
52-Week Low | $41.33 | $49.39 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
VTIP trades at $49.75 with minimal daily movement (+0.04%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The ETF focuses on short-term inflation-protected securities, offering minimal interest-rate sensitivity. Recent institutional activity includes 55 North Private Wealth increasing its position by 12.2% in Q2 2026.
Outlook remains cautious given bearish technical signals and persistent inflation concerns. The fund provides inflation hedging with reduced rate risk, but limited growth potential and competitive TIPS alternatives present challenges. Investors seeking short-duration inflation protection may find value, though overall market sentiment suggests tempered expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
